logo
  

Ardelyx Awaiting Next Steps From FDA To Resubmit NDA For Tenapanor For Hyperphosphatemia

Biopharmaceutical company Ardelyx, Inc. (ARDX) announced Wednesday that the company has met with the U.S. Food and Drug Administration (FDA) in a Type A meeting, but was not provided sufficient clarity on what constitutes "clinical relevance of the magnitude of treatment effect" and continues to await additional information regarding the path forward for the company's New Drug Application (NDA) for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

The company said it continues to be extremely disappointed and surprised by the lack of clarity from the FDA on the next steps to resubmit the NDA even after they have conducted the requisite registration studies, which met all primary and key secondary endpoints with no safety or other identified issues.

The company has made the extremely difficult decision to implement a restructuring plan that includes a significant reduction in operating costs and 65% of workforce to preserve cash resources and extend cash runway. It retained only the key employees needed to continue to support the regulatory process and work to achieve the goal to gain approval for tenapanor for hyperphosphatemia.

The restructuring plan is expected to be completed in December 2021. The company estimates that it will incur aggregate restructuring charges of approximately $2.3 million, which will be recorded primarily in the fourth quarter 2021, related to severance payments and other employee-related costs.

In July 2021, Ardelyx announced that it had received a complete response letter (CRL) from the FDA regarding the company's NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
RELATED NEWS
Follow RTT